CTA Sets the Reference Standard for Leadless Pacemaker Positioning
A single-center pilot study at Allegheny Health Network is testing a deceptively simple question with major procedural implications: how accurately do standard imaging tools identify the final position of a newly implanted leadless pacemaker? The trial will compare implanting electrophysiologist estimates, fluoroscopic interpretation, and transthoracic echocardiography TTE against cardiac computed tomography angiography CTA, which serves as the gold standard for anatomic location.
The study is focused on patients receiving a new Micra VR or AV2 device. In practice, the question matters because leadless pacing removes the pocket and transvenous lead, but shifts procedural risk toward right ventricular positioning, where overly deep or poorly judged deployment can raise the threat of right ventricular perforation. If imaging can localize the device more reliably in real time, operators may gain a safer framework for deployment and repositioning decisions.
The protocol is prospective, open-label, and small by design, with an estimated enrollment of 20 adults. It is built as a diagnostic study rather than a therapeutic comparison, and its central endpoint is not symptom relief or long-term pacing performance. Instead, the investigators are measuring whether bedside and procedural imaging can correctly predict where the device actually sits inside the heart.
A single sentence captures the core clinical issue: fluoroscopy can show where a device is moving, but CTA can show where it truly landed.
Why Right Ventricular Precision Matters in Leadless Pacing
Leadless systems change the procedural geometry of pacemaker implantation. Without a lead threaded through the venous system and anchored in the right ventricle, the operator must judge depth, orientation, and wall contact from imaging cues that are sometimes imperfect. Those cues become even more important when the implant target is not merely a chamber, but a precise region within the ventricle that can influence stability and safety.
The study uses standard fluoroscopic views and right ventricular site nomenclature after the procedure. After implantation, the implanter and two independent electrophysiologists will estimate the position of the device using those fluoroscopic images. Each participant will also undergo TTE, and three independent assessments of the implant site will be recorded. Within 48 hours, CTA of the heart with contrast will provide the anatomical reference used to determine the actual implant location.
That workflow is clinically meaningful because fluoroscopy and echocardiography answer different questions. Fluoroscopy is strong for procedural navigation and device delivery, but it is limited by projectional distortion and overlap of cardiac structures. TTE can offer a direct look at chamber anatomy and device relationship to the wall, yet image quality is sensitive to body habitus, lung disease, and acoustic windows. CTA, by contrast, can define spatial relationships with much greater anatomic precision, although it is still subject to contrast exposure and radiation burden.
TTE as the Main Candidate for Safer Bedside Guidance
Investigators hypothesize that TTE-guided implantation may improve both safety and accuracy of leadless pacemaker placement. That hypothesis is biologically and procedurally plausible. Real-time echocardiographic visualization can help operators identify the right ventricle’s contours, assess the relationship of the device to septal and apical regions, and potentially reduce the uncertainty that drives unnecessary repositioning or suboptimal final placement.
The study’s imaging comparison is especially relevant for a device class in which final placement can be difficult to judge from fluoroscopy alone. A small shift in the implant site may have outsized consequences when the device is meant to remain fully intracardiac and self-contained. For that reason, the trial is not simply asking which modality looks prettier on screen; it is asking which modality most faithfully maps the actual implant site.
The protocol also builds in a practical assessment of image quality. Baseline characteristics such as body mass index, chronic obstructive pulmonary disease, left ventricular ejection fraction, implant technique, and electrocardiographic parameters at final position will be examined alongside fluoroscopy and TTE image quality. The study will also evaluate whether operators can acquire specific echocardiographic views, including triangle or Koch and Bachmann area views, which may influence how well the implant site can be visualized.
Jugular Versus Femoral Access Adds a Procedural Layer
The secondary endpoints extend beyond imaging accuracy into procedural technique. Jugular and femoral implant approaches will be compared for timing, repositioning attempts, and predicted implant location accuracy. Those measures matter because access route can affect catheter control, working angles, and the operator’s ability to steer the device toward the intended region of the right ventricle.
Shorter procedure time would matter only if it did not come at the cost of precision. Repositioning attempts, by contrast, may provide a more direct window into how confidently the operator can steer and stabilize the device during deployment. If one access strategy allows clearer imaging or more predictable alignment, it could reduce the trial-and-error often associated with complex intracardiac device placement.
The eligibility criteria keep the focus narrow. Adults aged 18 to 89 undergoing implantation of a new Micra VR or AV2 device may participate. Exclusions include pregnancy, breastfeeding, an existing device implant, breast or pectoral implants, known iodinated contrast allergy, and a glomerular filtration rate below 45 unless the patient is on dialysis. Those exclusions reflect the realities of CTA-based protocols, where contrast safety and image quality are integral to the design.
Small Sample, Focused Question, Limited Generalizability
The planned enrollment of 20 patients makes this a pilot study, not a definitive practice-changing trial. Its purpose is to generate feasibility data and early accuracy estimates, not to settle the field. Even so, pilot studies often define whether a larger imaging-guided implantation strategy is worth pursuing, especially in procedure-heavy domains where technical nuance can directly affect safety.
This design also means the study will not answer every clinically important question. It will not establish long-term device outcomes, pacing thresholds over time, or rates of perforation in a statistically powered way. It will not determine whether one imaging modality improves survival or reduces hospitalizations. What it can do is show whether current imaging habits align with an anatomic standard strongly enough to justify broader use of TTE in routine implantation workflows.
The gold standard CTA readout will be central. If fluoroscopy and TTE systematically disagree with CTA, the trial will expose a gap between what operators think they see and where the device actually resides. If TTE tracks CTA closely, the case for using echocardiography as a procedural adjunct becomes much stronger, particularly in patients whose anatomy or body habitus makes fluoroscopic judgment less reliable.
A Diagnostic Trial With Direct Procedural Consequences
Leadless pacing was designed to simplify cardiac rhythm management, but the absence of a transvenous lead transfers much of the procedural burden onto implantation accuracy. This study confronts that burden directly. It tests whether multimodality imaging can narrow uncertainty at the moment when the device is still adjustable, before a mistaken final position becomes a permanent problem.
The design is open-label, prospective, and single-center, with recruitment centered in Pittsburgh. Last posted in early November 2026, the study is still recruiting and is scheduled to complete in 2028. Its device focus is specific, its imaging sequence is clear, and its clinical question is narrow enough to be testable.
If the final CTA comparisons show meaningful discordance between standard fluoroscopy and actual device position, that finding would immediately reshape how implanters think about intraprocedural confirmation. If TTE performs well, the trial could support a more prominent role for bedside echo in leadless pacemaker implantation, especially where safer positioning depends on visual certainty rather than fluoroscopic approximation.